실시간 바이오 인텔리전스 · ADC · CGT

함께 비교하는 진짜 ADC · Antibody · CGT 데이터

8,428+프로그램
40+FDA 승인
3,743+모집 중
ADC 1032·Antibody 4683·CGT 2713차세대 추천 →·Data Tier →
8428프로그램40FDA 승인
26오늘 방문
1,479누적 방문
7303갱신 대기S–CData TierS/A/B차세대→Insight1032HER2 breast4683Antibody2713CGT→Psoriasis→NSCLC40FDA 승인
피드Data Tier차세대Insight

추천 비교

비교 도구 →
HER2 ADCEnhertu · Kadcyla · RC48CD19 CAR-TYescarta · KymriahPD-1Keytruda · Opdivo다발골수종Darzalex · BlenrepTROP2 ADCTrodelvy · Dato-DXd · SGNectin-4 · TROP2Padcev · Trodelvy건선 IL pathwayStelara · Cosentyx · SkyriziAnti-VEGF (안과)Eylea · LucentisAnti-TNFHumira · EnbrelIL-12/23Stelara · Skyrizi아토피·IL-13Dupixent · EbglyssPCSK9 · LDLRepatha · Praluent · LeqvioGLP-1 · incretinSemaglutide · Tirzepatide혈우병 유전자치료Hemgenix · Roctavian겸상적혈구 CGTCasgevy · Lyfgenia망막·DMD 유전자치료Luxturna · Elevidys

최근 활동

RSS →

빠른 검색 · 이슈 태그

인기최근 업데이트큐레이션임상 많은갱신 필요ORR최신Phase 3FDA승인프로그램 3,526개
다음 갱신 D-13 · 마지막 7월 21일
AntibodystaleRochePhase 2

RO5072759 (obinutuzumab, obinutuzumab (RO5072759))

Non-Hodgkin's Lymphoma · Non-Hodgkin's Lymphoma

#Non-HodgkinsLymphoma#Antibody#Phase2#항체#면역항체+2
임상시험 1상태 ACTIVE
CGTBiologicstaleHebei Taihe Chunyu Biotechnolog…Phase 1

CAR19-BCMA dual-target CAR-T (CAR19-BCMA dual-target CAR-T)

Multiple Myeloma · BCMA

#BCMA#CGT#Phase1#세포유전치료#CAR-T+3
임상시험 1상태 RECRUITING
AntibodyBiologicstaleTongji HospitalPreclinical

Mab Therapy (Mab Therapy)

NMO Spectrum Disorder · NMO Spectrum Disorder

#NMOSpectrumDisorder#Antibody#Preclinical#항체#면역항체+2
임상시험 1상태 RECRUITING
AntibodystaleRochePhase 2

Obutinib or Decitabine, Rituximab, Compound Cyclophosphamide Tablets and Prednisone (Obutinib or Decitabine, Rituximab, Compound Cyclophosphamide Tablets and Prednisone)

Newly Diagnosed Diffuse Large B-cell Lymphoma · Newly Diagnosed Diffuse Large B-cell Lym

#NewlyDiagnosedDiffuseLargeB-cell#Antibody#Phase2#항체#면역항체+2
임상시험 1상태 RECRUITING
AntibodystaleRochePhase 3

rituximab (Rituxan, Originator rituximab - Rituxan ® or MabThera ®)

Rheumatoid Arthritis · Rheumatoid Arthritis

#RheumatoidArthritis#Antibody#Phase3#항체#면역항체+2
임상시험 1상태 ACTIVE
AntibodystaleRochePhase 3

GP2013 - A Proposed biosimilar rituximab (GP2013 - A Proposed biosimilar rituximab)

Rheumatoid Arthritis · Rheumatoid Arthritis

#RheumatoidArthritis#Antibody#Phase3#항체#면역항체+2
임상시험 1상태 ACTIVE
AntibodystaleSpectrum Pharmaceuticals, IncPhase 2

indium-111-ibritumomab tiuxetan (indium-111-ibritumomab tiuxetan)

Multiple Myeloma · Multiple Myeloma

#MultipleMyeloma#Antibody#Phase2#항체#면역항체+2
임상시험 1상태 DISCONTINUED
AntibodystaleGlaxoSmithKlinePhase 2

tositumomab (tositumomab)

Lymphoma, B-Cell · Lymphoma

#Lymphoma#Antibody#Phase2#항체#면역항체+3
효능 ORR 1%임상시험 1상태 ACTIVE
AntibodystaleGlaxoSmithKlinePhase 2

Tositumomab and Iodine I 131 Tositumomab (Anti-B1 Antibody and Iodine-131 Anti-B1 Antibody, Anti-B1 Antibody and Iodine-131 Anti-B1 Antibody (Tositumomab and Iodine I 131 Tositumomab))

Lymphoma, Non-Hodgkin · Lymphoma, Non-Hodgkin

#LymphomaNon-Hodgkin#Antibody#Phase2#항체#면역항체+4
임상시험 1상태 ACTIVE
AntibodystaleRochePhase 3

High-dose Epirubicin Combined with CVP ± Rituximab (High-dose Epirubicin Combined with CVP ± Rituximab)

Diffuse Large B-cell Lymphoma · Diffuse Large B-cell Lymphoma

#DiffuseLargeB-cellLymphoma#Antibody#Phase3#항체#면역항체+2
임상시험 1상태 ACTIVE
AntibodystaleRochePhase 3

Standard-dose Epirubicin Combined with CVP ± Rituximab (Standard-dose Epirubicin Combined with CVP ± Rituximab)

Diffuse Large B-cell Lymphoma · Diffuse Large B-cell Lymphoma

#DiffuseLargeB-cellLymphoma#Antibody#Phase3#항체#면역항체+2
임상시험 1상태 ACTIVE
AntibodystalePfizerPhase 1

PF-07901801 (Maplirpacept, Maplirpacept (PF-07901801))

Lymphoma; Multiple Myeloma · Lymphoma

#Lymphoma#Antibody#Phase1#항체#면역항체+3
임상시험 1상태 DISCONTINUED
AntibodystaleRochePhase 2

Pegylated Liposomal Doxorubicin (Doxil, Pegylated Liposomal Doxorubicin, Pegylated Liposomal Doxorubicin (Doxil) and Rituximab)

Non-Hodgkin's Lymphoma; Burkitt Lymphoma · Non-Hodgkin's Lymphoma

#Non-HodgkinsLymphoma#Antibody#Phase2#항체#면역항체+3
임상시험 1상태 DISCONTINUED
AntibodystaleJunshi BiosciencesPhase 2

Toripalimab, Rituximab (Toripalimab, Rituximab)

Diffuse Large B Cell Lymphoma; High-grade B-cell Lymphoma · Diffuse Large B Cell Lymphoma

#DiffuseLargeBCellLymphoma#Antibody#Phase2#항체#면역항체+3
임상시험 1상태 ACTIVE
AntibodystaleAstraZeneca Rare DiseaseApproved

Eculizumab+IVMP (Eculizumab+IVMP)

Neuromyelitis Optica Spectrum Disorder Attack · Neuromyelitis Optica Spectrum Disorder A

#NeuromyelitisOpticaSpectrumDisor#Antibody#Approved#항체#면역항체+2
임상시험 1상태 RECRUITING
CGTBiologicstaleChinese PLA General HospitalPhase 1

KRAS-EphA-2-CAR-DC (KRAS-EphA-2-CAR-DC)

Solid Tumor, Adult; EphA2 Overexpression · Solid Tumor, Adult

#SolidTumorAdult#CGT#Phase1#세포유전치료#CAR-T+5
임상시험 1상태 RECRUITING
AntibodystaleFeng JinzhouPreclinical

Inebilizumab (Inebilizumab)

Neuromyelitis Optica Spectrum Disorders · Neuromyelitis Optica Spectrum Disorders

#NeuromyelitisOpticaSpectrumDisor#Antibody#Preclinical#항체#면역항체+2
임상시험 1상태 ACTIVE
AntibodystaleRochePhase 2

ZR2 (Zanubrutinib, Lenalidomide and Rituximab, Zanubrutinib, Lenalidomide and Rituximab (ZR2))

Diffuse Large B Cell Lymphoma · Diffuse Large B Cell Lymphoma

#DiffuseLargeBCellLymphoma#Antibody#Phase2#항체#면역항체+2
임상시험 1상태 RECRUITING
AntibodystaleRochePhase 3

Perfusion of treatment Rituximab (Perfusion of treatment Rituximab)

Multiple Sclerosis; Relapsing-remitting Multiple Sclerosis · Multiple Sclerosis

#MultipleSclerosis#Antibody#Phase3#항체#면역항체+3
임상시험 1상태 RECRUITING
AntibodystaleRennes University HospitalPhase 3

Perfusion of treatment Ocrelizumab (Perfusion of treatment Ocrelizumab)

Multiple Sclerosis; Relapsing-remitting Multiple Sclerosis · Multiple Sclerosis

#MultipleSclerosis#Antibody#Phase3#항체#면역항체+3
임상시험 1상태 RECRUITING
CGTBiologicstaleNanjing Legend Biotech Co.Phase 1

LCAR-B4822M CAR-T Cell Immunotherapy (LCAR-B4822M CAR-T Cell Immunotherapy)

Refractory or Relapsed Multiple Myeloma · FRα

#FR#CGT#Phase1#세포유전치료#CAR-T+3
임상시험 1상태 ACTIVE
AntibodystaleRochePhase 2

Bendamustine, Rituximab, Lenalidomide (Bendamustine, Rituximab, Lenalidomide)

Chronic Lymphocytic Leukemia · Chronic Lymphocytic Leukemia

#ChronicLymphocyticLeukemia#Antibody#Phase2#항체#면역항체+2
임상시험 1상태 ACTIVE
AntibodystaleRochePhase 2

Intrathecal Rituximab (Intrathecal Rituximab)

Leukemia; Lymphoid Malignancies · Leukemia

#Leukemia#Antibody#Phase2#항체#면역항체+3
효능 ORR 0%임상시험 1상태 DISCONTINUED
AntibodystaleBiogenPhase 2

FCR + Lumiliximab (FCR + Lumiliximab)

Chronic Lymphocytic Leukemia · Chronic Lymphocytic Leukemia

#ChronicLymphocyticLeukemia#Antibody#Phase2#항체#면역항체+2
임상시험 1상태 DISCONTINUED
AntibodystaleRochePhase 1

bendamustine, rituximab, ibrutinib (BR-I, BR-I (bendamustine, rituximab, ibrutinib))

Mantle Cell Lymphoma; Lymphoma · Mantle Cell Lymphoma

#MantleCellLymphoma#Antibody#Phase1#항체#면역항체+3
임상시험 1상태 ACTIVE

129 / 142 페이지

← 이전다음 →
전체 8,428개 프로그램 보기